Global Transdermal Devices Industry for Drug Delivery (2019 to 2024) - In-depth Market and Competitive Analyses -

DUBLIN--()--The "Drug Delivery: Transdermal Devices" report has been added to's offering.

In 2019, global sales of transdermal patch products targeting the conditions covered by this analysis totalled nearly $4.9bn and is expected to increase at a CAGR of 2.4% over the forecast period, reaching $5.5bn in 2024.

The neurological disorder patches segment is expected to grow at the fastest rate, with a 3.7% CAGR over the forecast period as a result of the large market size and large potentially targetable patient caseload, while the pain management patches market is expected to experience the most dollar sales growth through 2024. Market drivers include the increasing prevalence of CVD and other associated disorders as the population ages, and improved patient compliance with patch-based pharmacology compared to oral medication. Limiters include declines in mature market segments and strong competition from oral pharmaceuticals and generic equivalents.

This report provides:

  • An overview of transdermal drug delivery technology, including active and passive transport systems
  • Key epidemiology data on the prevalence of angina pectoris, hypertension, Alzheimer's disease, ADHD, major depressive disorder, Parkinson's disease, menopause, osteoporosis, cancer-related pain, and post-herpetic neuralgia in major world regions
  • Related product portfolios offered by leading manufacturers
  • Top selling transdermal drug delivery devices, as well as emerging products under development
  • In-depth market and competitive analyses for 2019-24 for the US, five major European markets, Japan, and RoW markets.

Key Topics Covered:

1. Transdermal Drug Delivery Technology

1.1 Technology.

1.1.1 Passive transdermal transport systems

1.1.2 Active transdermal transport systems

1.2 Clinical applications

1.3 Bibliography

2. Transdermal Drug Delivery Systems

2.1 Cardiovascular disease management.

2.1.1 Angina pectoris

2.1.2 Hypertension

2.1.3 Products

2.1.4 Emerging products

2.2 Neurological disorder management

2.2.1 Attention deficit hyperactivity disorder

2.2.2 Alzheimer's disease

2.2.3 Major depressive disorder.

2.2.4 Parkinson's disease

2.2.5 Products

2.2.6 Emerging products

2.3 Hormone replacement therapy

2.3.1 Menopause

2.3.2 Osteoporosis

2.3.3 Products

2.3.4 Emerging products

2.4 Pain management

2.4.1 WHO analgesic ladder

2.4.2 Products

2.6 Bibliography

3. Transdermal Drug Delivery Systems Market

3.1 Cardiovascular disease management

3.1.1 Market analysis

3.1.2 Competitive analysis

3.2 Neurological disorder management

3.2.1 Market analysis

3.2.2 Competitive analysis

3.3 Hormone replacement therapy

3.3.1 Market analysis

3.3.2 Competitive analysis

3.4 Pain management

3.4.1 Market analysis

3.4.2 Competitive analysis

3.5 Bibliography

Companies Mentioned

  • WHO
  • Boehringer Ingelheim
  • Mylan Technologies
  • Mayne Pharma
  • UCB Group
  • Novartis
  • Hisamitsu Pharmaceutical
  • Bayer
  • Endo Pharmaceuticals

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900